PLX — Protalix BioTherapeutics, Inc.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 1006281 ·
Last close
$2.88
Market Cap
$242.84M
52W High
$3.19
52W Low
$1.65
ADV30
993,518
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 21,925,000 | 14,049,000 | 4,047,000 | 3,961,000 | 118,242,000 | 22,035,000 | 37,693,000 |
| Jun 2026 | 19,896,000 | 12,134,000 | 4,672,000 | 3,777,000 | 110,336,000 | 27,420,000 | 38,932,000 |
| Mar 2026 | 33,750,000 | 29,623,000 | 21,146,000 | 18,317,000 | 102,336,000 | 41,001,000 | 35,107,000 |
| Dec 2025 | 9,122,000 | 4,503,000 | -4,658,000 | -5,504,000 | 82,346,000 | 14,680,000 | 34,116,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$17,559,000
Investing CF
$-14,335,000
Financing CF
$4,879,000
CapEx
$-2,494,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.35
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-358,942,000
Inventory
$34,297,000
Receivables
$13,913,000
ST Investments
$26,503,000
EBIT TTM
$26,941,000
Pretax Income TTM
$25,847,000
Interest Exp TTM
$1,094,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$84,693,000
EBITDA
$26,825,000
Free Cash Flow
$11,424,375
Enterprise Value
$217,779,712
Total Cash
$48,538,000
Total Debt
$9,145,000
Shares Out
84,318,923
Trailing EPS
$0.24
Book Value
$0.98
ROE
30.8%
ROA
15.7%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 52,744,000 | -5,500,000 | -6,604,000 | 82,346,000 | 34,116,000 | 48,230,000 | -11,993,000 |
| Dec 2024 | 53,399,000 | 3,917,000 | 2,932,000 | 73,417,000 | 30,206,000 | 43,211,000 | 8,674,000 |
| Dec 2023 | 65,494,000 | 10,460,000 | 8,312,000 | 84,434,000 | 50,865,000 | 33,569,000 | -1,318,000 |
| Dec 2022 | 47,638,000 | -13,014,000 | -14,927,000 | 55,787,000 | 66,427,000 | -10,640,000 | -25,000,000 |
TTM Snapshot
Revenues TTM
$80,619,000
NetIncome TTM
$18,945,000
OpCashFlow TTM
—
Assets (Latest)
$110,336,000
Forward EPS
$0.62
Max Pain — expiry 2027-02-19
max pain strike: $2.50 · spot: $3.02 · call oi: 4,026 · put oi: 746
Expected Move to 2027-02-19:
±$0.95
(31.46%) —
implied range
$2.07 –
$3.97
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IPSC | Century Therapeutics, Inc. | $248.79M | $1.37 | — |
| LXEO | Lexeo Therapeutics, Inc. | $234.24M | $2.86 | — |
| PROK | PROKIDNEY CORP. | $229.87M | $1.10 | — |
| OCGN | Ocugen, Inc. | $256.75M | $0.76 | — |
| ALLO | Allogene Therapeutics, Inc. | $257.08M | $0.74 | — |
News headlines (Yahoo Finance, 1h cache)
PLX: Elfabrio Estimates Up, Again
2026-11-11 16:01 · Yahoo
Protalix BioTherapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-11 03:02 · Yahoo
Protalix: Q3 Earnings Snapshot
2026-11-10 11:56 · Yahoo
Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results
2026-11-10 11:45 · Yahoo
Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations
2026-11-09 11:45 · Yahoo
Protalix BioTherapeutics to Announce Third Quarter 2026 Financial Results and Business Update on November 10, 2026
2026-11-03 11:50 · Yahoo
Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences
2026-09-08 10:45 · Yahoo
Protalix BioTherapeutics Inc (PLX) (Q2 2026) Earnings Call Highlights: Net Income Surges to $3. ...
2026-08-12 23:04 · Yahoo
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
2026-08-12 10:50 · Yahoo
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026
2026-08-05 10:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.